• Join
  • Login
  • Contact

Search abstracts


  • In: A7 - Cancer immunotherapy: using drugs and cells to exploit our immune systems on Friday, 2 October 2015, 09:00-12:00
  • At: Düsseldorf (Germany) (2015)
  • Type: Presentation
  • By: HARVEY, R. Donald (Winship Cancer Institute of Emory University, Hematology/Medical Oncology, Avondale Estates, United States)
  • Co-author(s): R. Donald Harvey
  • Abstract:

    Therapeutic antibodies that block the programmed cell death protein-1 (PD-1) immune checkpoint pathway prevent T-cell downregulation and promote immune responses against a number of cancer types. The US FDA has approved pembrolizumab for the treatment of advanced melanoma and nivolumab for advanced melanoma and squamous cell non-small cell lung


  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses